A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
As we go into the Bank Holiday weekend, the changeable weather pattern looks set to continue.
Labour leadership contender Andy Burnham has called for the House of Lords to be scrapped, saying it's "a national embarrassment".
Jamaican sprinter Usain Bolt has met the cameraman who crashed into him on a Segway.